An interventional study of Continuous positive airway pressure in Sleep Apnea, Obstructive, sponsored by Alberto Alonso Fernandez. Completed at 2 sites in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Alberto Alonso Fernandez · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Sleep Apnea, Obstructive with a site in Spain — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Spain.
Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, this one is the 28th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2020, is one of 46 with no phase, and was the 56th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →16 of the 82 studies in Sleep Apnea, Obstructive with a site in Spain are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Australia and 8 more countries
Ages 18+
Sociedad Española de Neumología y Cirugía Torácica · Sites in Spain
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2020.
This study's enrollment of 136 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 128 across the 60 interventional studies, 338 across the 21 observational. Of the 44 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 82 have an industry lead sponsor. The 10 most frequent:
Alberto Alonso Fernandez is the lead sponsor of 2 studies on the registry; none are open to participants now.
Alberto Alonso Fernandez has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
3 of the studies in Sleep Apnea, Obstructive with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07001215Hospital Universitario Ramon y CajalEffect of CPAP Versus APAP in Patients With Obesity Undergoing Bariatric Surgery Protocol | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To compare biomarkers of Alzheimer's disease in plasma samples from patients with Obstructive sleep apnea (OSA) and without OSA. 2) To determine if CPAP reduces biomarkers of Alzheimer's disease in plasma samples.
Randomized, parallel group, non-blinded, controlled clinical trial compared with conventional treatment.
A. Protocol and intervention Patients with an Apnea-Hypopnea index (AHI)>30 h-1 will be assigned, using a 1:1 randomization table, to lifestyle recommendations treatment or to lifestyle recommendations plus nasal CPAP, for a period of 4 months. CPAP pressure will be titled with automatic using an AutoSet II device, ResMed.
B. Sample size For the estimation of the sample size, previous data were used (PLoS ONE 2019;14(9): e0221255). In this case, in order to compare the effect of CPAP it would be necessary to randomize a total of 100 patients with OSA and 30 control subjects.
C. Ethical considerations
D. Methods.
. Polysomnography. It will be used as a screening test previous the randomization of the included patients. The exploration and its interpretation will be carried out following the recommendations of the American Academy of Sleep Medicine. Based on the results of this test, only those patients with an AHI will continue in the study when AHI >30 h-1. In these patients the determinations listed below will be carried out immediately before randomization (visit 1), at 4 weeks (visit 2), 16 weeks (visit 4) of allocation to the corresponding treatment group
Statistic analysis The data will be expressed as mean ± standard deviation, median (interquartile range) or percentage, depending on their type and distribution. For comparison between groups Student's t-test, the U-Mann-Whitney or the chi-square test will be used, as appropriate. The relations between variables will be analyzed using Pearson's correlation and multiple linear regression analysis. The effect of treatment will be evaluated using general linear models and repeated measures analysis of variance, with multiple comparisons post-hoc using the Bonferroni test. A multiple logistic regression model will be applied to determine the related variables with a response to treatment. Values of p \<0.05 will be considered statistically significant. The statistical study will be performed with the SPSS program version 22.0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diet and general life style recommendations plus continuous positive airway pressure (CPAP).
Device: Continuous positive airway pressure
Diet and general life style recommendations.
Continuous positive airway pressure
Change from baseline in β-amyloid 40 (Aβ-40 and/or Aβ42) concentration
To compare the change in Aβ-40 and/or Aβ42 levels between the patients allocated to CPAP group and the control group
Time frame: 4 months
β-amyloid 40 (Aβ-40 and and/or Aβ42) concentration in OSA and in non-OSA patients
To compare Aβ-40 and/or Aβ42 levels between OSA and non-OSA patients
Time frame: Baseline
Phospho-Tau (P-Tau) concentration in OSA and in non-OSA patients
To compare plasma concentrations of P-Tau in subjects with/without OSA.
Time frame: Baseline
Apolipoprotein E (APOE) concentration in OSA and in non-OSA patients
To compare plasma concentrations of Apolipoprotein E (APOE) in subjects with/without OSA.
Time frame: Baseline
Neurofilament light chain (NfL) concentration in OSA and in non-OSA patients
To compare plasma concentrations of NfL in subjects with/without OSA.
Time frame: Baseline
Microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients
To compare microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients
Time frame: Baseline
Microbiota population abundance from stool and nasopharyngeal samples in OSA and in non-OSA patients
To compare microbiota abundance from stool samples and nasopharyngeal samples in OSA and in non-OSA patients
Time frame: Baseline
Microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients
To compare microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients
Time frame: Baseline
Associations of microbiota population diversity from stool and nasopharyngeal samples in OSA with biomarkers of Alzheimer's Disease
To relate microbiota population diversity from stool and nasopharyngeal samples to biomarkers of Alzheimer's Disease
Time frame: Baseline
Associations of microbiota population abundance from stool and nasopharyngeal samples in OSA with biomarkers of Alzheimer's Disease
To relate microbiota population abundance from stool and nasopharyngeal samples to biomarkers of Alzheimer's Disease
Time frame: Baseline
Associations of microbiota population color maps from stool and nasopharyngeal samples in OSA with biomarkers of Alzheimer's Disease
To relate microbiota population color maps from stool and nasopharyngeal samples to biomarkers of Alzheimer's Disease
Time frame: Baseline
To evaluate the relationship of biomarkers of Alzheimer's disease and oropharyngeal and gut microbiota with the main classical markers of OSA and nocturnal hypoxic burden.
To evaluate the relationship of biomarkers of Alzheimer's disease and oropharyngeal and gut microbiota with the main classical markers of OSA (AHI, AHI in REM, Di, arousals index, slow wave sleep time, SpO2 time\<90%, mean nocturnal SpO2, minimum SpO2, 3% and 4% desaturations index), as well as with nocturnal hypoxic burden related to respiratory events.
Time frame: Baseline
Associations between CPAP effects on oropharyngeal and gut microbiota, and biomarkers of Alzheimer's disease.
To assess whether CPAP treatment modifies microbiota population diversity, abundance, and color maps from stool samples and nasopharyngeal samples of patients with OSA, and whether these changes correlate with variations in biomarkers of Alzheimer's disease
Time frame: 4 months
Change from baseline in biomarkers of Alzheimer's disease, and oropharyngeal and gut microbiota samples of patients with OSA according to the baseline hypoxic burden level and residual hypoxia.
To assess whether residual hypoxia and baseline hypoxic burden results in a different response to CPAP/conservative treatment on biomarkers of Alzheimer's disease, and oropharyngeal and gut microbiota in patients with OSA.
Time frame: 4 months
To determine the relationship between compliance with CPAP treatment and the response on biomarkers of Alzheimer's disease and oropharyngeal and gut microbiota.
To assess whether CPAP compliance (\>4 hours) results in a different response to biomarkers of Alzheimer's disease, and oropharyngeal and gut microbiota in patients with OSA.
Time frame: 4 months
Phosphorylated tau at threonine 217 (p-Tau217)
To compare p-Tau217 levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and lifestyle recommendations treatment, and the lifestyle recommendations treatment alone.
Time frame: Baseline and 4 months
Ran from Jul 2020 to primary completion in Jul 2026, 71 months.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 71 months is above that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Apr 2025 → Jul 2026 and completion May 2025 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alberto Alonso Fernandez